Lates News

On June 15th, Novo Nordisk's global executive team announced during their visit to China that they will be investing an additional 200 million RMB in their strategic production base in Tianjin to increase the assembly production capacity of their 1.5ml prefilled injection pens. The project, once completed, will significantly increase the production capacity and supply efficiency of related high-quality products. Since 2003, Novo Nordisk has invested over 17 billion RMB in China.